DIRS.INFO The most relevant business & tech news

Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that's in the business of water quality. When we receive Veralto shares on Monday, as all Danaher shareholders will, we intend to keep them, based on their current expected value. A "when-issued" market was established Wednesday for both Danaher and Veralto stock, providing a first look at how investors are valuing the companies on their own. Investors will receive one share in Veralto for every three shares of Danaher they own. The caveat is that spin-off debuts can see substantial volatility, and if Veralto shares were to receive a big pop, our discipline may require us to capitalize on that and take profits.

Persons: it's, Danaher, Jim Cramer, Jim Cramer's, Veralto, we'll, –, disinfect, That's, we've, attractively, We're, Jim, Pavlo Gonchar Organizations: Deutsche Bank, Zebra Technologies, CNBC, Getty Locations: Veralto, Danaher, DHR, Wells, York

☆ This chipmaker is still one step ahead of the competition
▼ + stars: | 2023-09-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. Nvidia still one step ahead In a research note Friday, Citigroup assessed Club name Nvidia 's (NVDA) next generation B100 graphics processing unit, which is expected to be launched next year. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, we're, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Treasury, West Texas Intermediate, Nvidia, Citigroup, Citi Locations: Stocks, Veralto, Danaher, DHR

☆ Health care has had a tough year. Where we stand on our 5 stocks in the sector
▼ + stars: | 2023-09-22 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +12 min

Bausch Health (BHC) is a different case. Key points Health-care stocks outperformed the broader U.S. stock market last year, but this year it's been much-tougher sledding for the sector due to a variety of headwinds. We feel comfortable owning our three other primary health care stocks: GE Healthcare, Humana and Danaher. In recent weeks, analysts at Wells Fargo and Citigroup have started coverage of GE Healthcare with buy ratings. The analysts at Jefferies now rate Bausch Health stock a buy, with a price target increase to $16 per share from $9.

Persons: There's Eli Lilly, Eli Lilly, That's, Eli Lilly's, Ryan Issakainen, we're, Issakainen, –, Stryker, Jim Cramer, it's, Jim, We've, Bausch, BHC, We're, I'm, Jefferies, Jim Cramer's, Frederick Florin Organizations: GE Healthcare, Health, Federal Reserve, First Trust Advisors, Humana, Medicare, Dow, UnitedHealth, GE, General Electric, —, Citigroup, Jefferies, CNBC, AFP, Getty Locations: what's, China, STE, Biogen, Wells, Bausch, Fegersheim, France

☆ This health-care stock is set to complete another spin-off. Here's what it means for our position in the stock
▼ + stars: | 2023-09-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

Veralto will consist of two primary divisions – water quality and product quality & innovation – which generated nearly $5 billion in combined sales in 2022 under the Danaher roof. The water quality unit contributed about 60% of that figure. Bottom line We expect to stay invested in both Danaher and Veralto once the spin-off is completed and the tax-free share distribution occurs on Sept. 30. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

Persons: we're, Jennifer Honeycutt, Melissa Aquino, –, Sameer Ralhan, Ralhan, Danaher, Veralto, they're, Jim Cramer's, Jim Cramer, Jim, Joe Raedle Organizations: Wall Street, Veralto's, CNBC, Miami, Getty Locations: Danaher, Veralto, New York, U.S, . New York City

☆ This life-sciences leader continues to demonstrate a nimble M&A strategy
▼ + stars: | 2023-08-28 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. Equities rise Watch Danaher's portfolio A flurry of trades 1. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jerome Powell's, Danaher, Estee Lauder, Walt Disney, Jim Cramer's, Jim Organizations: CNBC, Federal, Treasury, West Texas, Micro Devices, Broadcom, GE HealthCare Technologies, Starbucks, Jim Cramer's Charitable Locations: Jackson Hole , Wyoming, Danaher

☆ Danaher cut its outlook for 2023, but we're maintaining our rating — here's why
▼ + stars: | 2023-07-25 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Life sciences and medical diagnostics company Danaher (DHR) delivered a second-quarter earnings beat on Tuesday, but lowered its outlook for the year. When excluding the impact of Covid-related tests and products, Danaher realized base-business core sales growth of 2%. As a result, management was once again forced to downwardly revise their sales growth outlook for the year. We predict a bioprocessing bottom this year, early next year at the very latest, setting us for a rebound in organic revenue growth. This updated outlook represents a downward revision from the high-single-digit percentage decline previously expected on a core basis and the mid-single-digit percentage growth previously expected for the base business.

Persons: Danaher, Cash, Bioprocessing, That's, Sartorius, Cepheid, Jim Cramer's, Jim Cramer, Jim, Marisol Darge, Robert McCabe, Hyoung Chang Organizations: Revenue, Management, Wall, Biotechnology, pharma, CNBC, Kaiser Permanente Arapahoe Medical, Getty Locations: DHR, China, Base, Centennial , Colorado, Denver

☆ Sales, spins and splits — what are the differences and why do they matter for investors like us?
▼ + stars: | 2023-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +20 min

Investors may get one share in the spun-out entity for every share of the parent company they owned. What's left of J & J will be focused on pharmaceuticals and medical technologies, which were responsible for over 84% of the company's total 2022 revenue of $94.94 billion. It underscores that once free of the parent company tethers a divested company can chart its own destiny. Those priorities may not have necessarily been wrong when considering J & J as the overall enterprise. We believe J & J and Danaher are poised to deliver two more examples.

Search resuls for: "Veralto"

7 mentions found